Dihexa

Quick Facts

Introduction

Dihexa (developmental code N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small, modified compound derived from angiotensin IV, the brain-active fragment of the angiotensin system. It emerged from academic research into the AT4 receptor system and is distinguished within the nootropic-peptide landscape by an unusual claim from its preclinical literature: it is reported to be a strikingly potent promoter of synaptogenesis, the formation of new functional synapses.

The conceptual appeal of Dihexa research is mechanistic. Rather than acting as a classical neurotransmitter or neurotrophic-factor mimetic, it is studied as a potentiator of hepatocyte growth factor (HGF) signaling through its receptor c-Met — a pathway tied to neuronal connectivity and plasticity. This sets it apart from the Semax/Selank lineage of regulatory peptides and from neurotrophic mimetics such as P-21.

This profile covers what Dihexa is, the structural modifications that give it metabolic stability and brain penetration, its proposed HGF/c-Met mechanism, the synaptogenesis research it appears in, and how it compares with related nootropic compounds. Related entries are catalogued in the peptide database.

What is Dihexa?

Dihexa is an angiotensin IV analogue developed by modifying the parent peptide to overcome the two limitations that prevent native angiotensin IV from being a practical research tool: rapid enzymatic degradation and poor passage across the blood-brain barrier. The molecule retains a compact tyrosine-containing core flanked by a hexanoic-acid (N-acyl) group and an aminohexanoic-acid extension.

Those modifications are what define it. The acyl cap and the aliphatic extension make the molecule highly lipophilic and metabolically stable, which is the basis for the reports that it is active even by oral administration — a rarity among peptide-derived nootropic candidates. Because it is so lipophilic, laboratory preparation typically relies on a co-solvent such as DMSO rather than water alone.

Molecular and structural characteristics

Unlike the water-soluble regulatory heptapeptides in the nootropic class, Dihexa is best described as a peptidomimetic small molecule. Its short backbone is heavily modified with aliphatic groups, shifting its physicochemical profile away from a typical peptide and toward a lipophilic, membrane-permeant compound. This is the structural reason its handling and pharmacokinetics differ markedly from peptides such as Semax.

Mechanism of action

The mechanism most emphasized in the Dihexa literature is potentiation of hepatocyte growth factor (HGF) signaling through the c-Met receptor. HGF and its receptor tyrosine kinase c-Met form a signaling system implicated in cell growth, migration, and — in the nervous system — synaptic connectivity. Research has proposed that Dihexa binds HGF and enhances its dimerization and ability to activate c-Met, amplifying downstream plasticity-related signaling.

This places Dihexa's mechanism in contrast with the rest of the nootropic-peptide class. Where Semax is studied for BDNF/NGF upregulation and Selank for GABAergic and neuroimmune modulation, Dihexa is studied as a growth-factor potentiator acting on a receptor tyrosine kinase. Its angiotensin IV origin connects it to the AT4 / insulin-regulated aminopeptidase (IRAP) system, which has independently been linked to memory facilitation.

The functional readout most associated with this signaling is synaptogenesis — the formation of new dendritic spines and functional synapses. Preclinical reports have described Dihexa promoting spine formation in hippocampal neurons at very low concentrations, which is the basis for the strong potency claims in its literature and for its study in models of cognitive impairment.

• Potentiation of HGF binding and c-Met receptor activation.
• Amplification of plasticity-related receptor tyrosine kinase signaling.
• Connection to the angiotensin IV / AT4 (IRAP) system.
• Promotion of dendritic spine formation and synaptogenesis.
• Activity reported at notably low concentrations in preclinical models.

Synaptogenesis and cognition research

The endpoint most associated with Dihexa is synaptic connectivity. In preclinical models the compound has been studied for its capacity to increase the number and function of synapses, and it has been examined in rodent paradigms of cognitive impairment, including models relevant to age-associated decline. The HGF/c-Met mechanism above is the proposed substrate for these observations.

Because the synaptogenesis hypothesis links it to learning and memory, Dihexa appears in the same broad research conversation as other nootropic peptides studied for cognition, including Semax and the neurotrophic mimetic P-21. Its distinct mechanism, however, means researchers treat it as mechanistically separate rather than interchangeable with the regulatory-peptide class.

Translational considerations

A recurring theme in Dihexa discussion is the gap between its striking preclinical reports and the limited body of independent, in-vivo, and human research. The HGF/c-Met pathway it targets is also active in non-neural tissues and is implicated in cell proliferation generally, which is why researchers note that a compound capable of potentiating this system warrants careful study of off-target and long-term effects before any translational conclusions are drawn.

Comparison: Dihexa vs Semax vs P-21

Dihexa is most usefully compared with Semax, an ACTH-derived peptide studied for neurotrophic upregulation, and with P-21, a neurotrophic-factor mimetic studied for neurogenesis. All three are investigated for cognition, but Dihexa is mechanistically distinct as an HGF/c-Met potentiator and as a lipophilic small molecule rather than a water-soluble peptide.

Because their mechanisms differ, Dihexa and Semax are studied as complementary rather than equivalent approaches to plasticity. Full entries for each are in the peptide database.

Half-life and pharmacokinetic considerations

Dihexa's pharmacokinetic identity is defined by the modifications that distinguish it from native angiotensin IV. Its metabolic stability and lipophilicity are reported to give it a substantially longer functional window than the parent peptide and to allow penetration of the blood-brain barrier — the properties behind reports of activity following oral administration, which is unusual for a peptide-derived compound.

Precise human pharmacokinetic parameters are not well established, reflecting the compound's predominantly preclinical evidence base. Researchers therefore treat statements about its duration and bioavailability as derived from animal and in-vitro work rather than from controlled human studies, and as an active area of investigation.

Reconstitution and handling considerations

Because Dihexa is highly lipophilic, it is generally not freely water-soluble. Laboratory preparation typically uses a co-solvent such as DMSO to dissolve the compound first, after which it may be diluted into a compatible vehicle for research use. This handling profile is a notable departure from the water-soluble peptides in the nootropic class.

When an aqueous working solution is prepared, the same general principles used for peptides apply, and the reconstitution calculator and reconstitution guide describe the underlying method for converting between mass and volume.

• Dissolve in DMSO or a compatible co-solvent before aqueous dilution.
• Confirm the prepared solution is clear before use.
• Protect from light and excess warmth.
• Avoid repeated freeze–thaw cycles of prepared solutions.

Storage considerations

Lyophilized or powdered Dihexa is most stable frozen at −20 °C, kept dry and away from light. Solutions, including DMSO stocks, are best refrigerated and protected from light, with repeated freeze–thaw cycles avoided. Aliquoting reduces how often a given solution is cycled.

Research limitations

Dihexa's research base is among the thinnest in the nootropic-peptide category relative to the strength of the claims made about it. Its most notable findings come from a small number of preclinical studies, with limited independent replication and essentially no controlled human research. Because its target pathway, HGF/c-Met, is active throughout the body and implicated in cell proliferation, the long-term and off-target implications of potentiating it are themselves open research questions. It is described here strictly for research reference.

• Most data are preclinical with limited independent replication.
• Controlled human pharmacokinetic and safety data are essentially absent.
• The HGF/c-Met target is active in non-neural tissues, raising off-target questions.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. Journal of Pharmacology and Experimental Therapeutics. 2013.Source
2. Benoist CC, Wright JW, Zhu M, et al. Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogs. Journal of Pharmacology and Experimental Therapeutics. 2011.
3. Wright JW, Harding JW. The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer's disease. Journal of Alzheimer's Disease. 2015.